Tenaya Therapeutics Inc(TNYA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TNYA Tenaya Therapeutics Inc

Post-Mkt 05-01 16:37:51 EDT

0.7058

+0.0147

+2.13%

盘后0.7100

+0.0042+0.60%

16:36 EDT

High0.7200	Low0.6887	Vol2.49M
Open0.6940	D1 Closing0.6911	Amplitude4.53%
Mkt Cap152.81M	Tradable Cap145.28M	Total Shares216.51M
T/O1.75M	T/O Rate1.21%	Tradable Shares205.84M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"TNYA","market":"US","secType":"STK","nameCN":"Tenaya Therapeutics Inc","latestPrice":0.7058,"timestamp":1777665600000,"preClose":0.6911,"halted":0,"volume":2486364,"hourTrading":{"tag":"盘后","latestPrice":0.71,"preClose":0.7058,"latestTime":"16:36 EDT","volume":9975,"amount":7077.83706,"timestamp":1777667787913,"change":0.0042,"changeRate":0.005951,"amplitude":0.019552},"delay":0,"changeRate":0.021270438431485943,"floatShares":205841252,"shares":216505900,"eps":-0.592248,"marketStatus":"Post-Mkt","change":0.0147,"latestTime":"05-01 16:37:51 EDT","open":0.694,"high":0.72,"low":0.6887,"amount":1747679.6765112001,"amplitude":0.04529,"askPrice":0.7113,"askSize":1254,"bidPrice":0.6901,"bidSize":15,"shortable":3,"etf":0,"ttmEps":-0.592248,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1777680000000},"marketStatusCode":4,"adr":0,"listingDate":1627617600000,"exchange":"NASDAQ","adjPreClose":0.6911,"preHourTrading":{"tag":"盘前","latestPrice":0.6911,"preClose":0.6911,"latestTime":"09:25 EDT","volume":17659,"amount":12252.951439600001,"timestamp":1777641926997,"change":0,"changeRate":0,"amplitude":0.01447},"postHourTrading":{"tag":"盘后","latestPrice":0.71,"preClose":0.7058,"latestTime":"16:36 EDT","volume":9975,"amount":7077.83706,"timestamp":1777667787913,"change":0.0042,"changeRate":0.005951,"amplitude":0.019552},"volumeRatio":0.73275,"impliedVol":1.6044,"impliedVolPercentile":0.5179},"requestUrl":"/m/hq/s/TNYA/tweets","defaultTab":"tweets","newsList":[{"id":"2631523087","title":"Tenaya Therapeutics Inc  expected to post a loss of 9 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2631523087","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631523087?lang=en_us&edition=fundamental","pubTime":"2026-04-30 04:04","pubTimestamp":1777493046,"startTime":"0","endTime":"0","summary":"Tenaya Therapeutics Inc  expected to post a loss of9cents a share - Earnings Preview Tenaya Therapeutics Inc TNYA.OQ TNYA.O is expected to  show a rise in quarterly revenue when it reports  results on","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nL8N41C39C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TNYA","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630239975","title":"Tenaya to present new RIDGE-1 TN-401 gene therapy data at ASGCT 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2630239975","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630239975?lang=en_us&edition=fundamental","pubTime":"2026-04-27 20:31","pubTimestamp":1777293104,"startTime":"0","endTime":"0","summary":"Tenaya Therapeutics announced new interim clinical data from its RIDGE-1 Phase 1b/2 trial of TN-401 gene therapy in adults with PKP2-associated arrhythmogenic right ventricular cardiomyopathy.Results will be presented in a late-breaking oral session at ASGCT on May 15, 2026, covering one-year findings from the first dose cohort plus early data from the second cohort.Update is set to include safety, biopsy, and efficacy readouts, positioning TN-401 as a potential disease-modifying approach that targets the underlying genetic cause.Data package spans two dose levels, supporting assessment of risk-benefit and dose selection as program advances.Tenaya also plans a webcast conference call around ASGCT to discuss the RIDGE-1 readout.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nNDL1m7MWm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00BN0W2T93.GBP","BK4139","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","IE00BN0W2W23.USD","BK4585","SG9999014013.SGD","LU0314104364.USD","LU2210149790.SGD","BK4112","IE00BGHQF748.EUR","SG9999014021.USD","IE00BN0W2V16.EUR","BK4539","TNYA","SG9999014005.SGD","NDAQ","LU2095319765.USD","LU2210150020.SGD","SG9999014039.USD","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630733399","title":"Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data From Ridge™-1 Phase 1B/2 Clinical Trial of Tn-401 Gene Therapy in Adults With Pkp2-Associated Arvc at Asgct 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2630733399","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630733399?lang=en_us&edition=fundamental","pubTime":"2026-04-27 20:30","pubTimestamp":1777293001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nTUA7VYKNW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TNYA","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627363215","title":"Tenaya Therapeutics announces annual shareholder meeting via webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2627363215","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627363215?lang=en_us&edition=fundamental","pubTime":"2026-04-16 21:01","pubTimestamp":1776344495,"startTime":"0","endTime":"0","summary":"Tenaya Therapeutics will hold its annual stockholders meeting virtually on May 27, 2026.Items up for a vote include election of three Class II directors to serve terms through 2029.Shareholders will also vote on ratifying Deloitte & Touche as independent registered public accounting firm for fiscal 2026.Another proposal seeks approval to amend and restate 2021 Equity Incentive Plan, including a one-time increase of 6,509,966 shares and removal of 4 million-share annual cap from evergreen provision while keeping 4% annual increase.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tenaya Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nNDL5WGtxl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","TNYA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627891463","title":"Tenaya’s TN-401: Differentiated PKP2 Gene Therapy Opportunity Underpins Favorable Risk–Reward and Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2627891463","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627891463?lang=en_us&edition=fundamental","pubTime":"2026-04-14 03:35","pubTimestamp":1776108923,"startTime":"0","endTime":"0","summary":"Cory Jubinville, PhD, an analyst from LifeSci Capital, maintained the Buy rating on Tenaya Therapeutics. The associated price target remains the sa...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/tenayas-tn-401-differentiated-pkp2-gene-therapy-opportunity-underpins-favorable-risk-reward-and-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/tenayas-tn-401-differentiated-pkp2-gene-therapy-opportunity-underpins-favorable-risk-reward-and-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","TNYA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618137838","title":"Tenaya Therapeutics Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2618137838","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618137838?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:38","pubTimestamp":1773319080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TNYA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 12, 2026 08:38 ET (12:38 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TNYA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618976367","title":"Tenaya Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2618976367","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618976367?lang=en_us&edition=fundamental","pubTime":"2026-03-12 04:55","pubTimestamp":1773262558,"startTime":"0","endTime":"0","summary":"Tenaya Therapeutics Inc reports results for the quarter ended December 31 - Earnings SummaryTenaya Therapeutics Inc TNYA.OQ reported a quarterly adjusted loss of 12 cents per share for the quarter end","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nL8N3ZZ2ZZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","TNYA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618975462","title":"Tenaya Therapeutics' Q4 net loss narrows, extends cash runway into H2 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2618975462","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618975462?lang=en_us&edition=fundamental","pubTime":"2026-03-12 04:37","pubTimestamp":1773261468,"startTime":"0","endTime":"0","summary":"Tenaya Therapeutics' Q4 net loss narrows, extends cash runway into H2 2027OverviewUS cardiac gene therapy developer's Q4 net loss narrowed to $20.18 mln, compared to analysts' expectations of a loss o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nL1N3ZZ1BT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALNY","BK4139","LU0109394709.USD","LU0882574055.USD","LU0114720955.EUR","LU0320765992.SGD","LU0889565916.HKD","BK4539","BK4585","TNYA","BK4548","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618975759","title":"Tenaya Therapeutics reports Q4 EPS (12c), consensus (12c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618975759","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618975759?lang=en_us&edition=fundamental","pubTime":"2026-03-12 04:27","pubTimestamp":1773260829,"startTime":"0","endTime":"0","summary":"“As we enter 2026, we are energized by the momentum and clinical advances achieved over the past year,” said Faraz Ali, CEO of Tenaya. “The encoura...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tenaya-therapeutics-reports-q4-eps-12c-consensus-12c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tenaya-therapeutics-reports-q4-eps-12c-consensus-12c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TNYA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618897342","title":"Tenaya Therapeutics Q4 EPS $(0.12) Beats $(0.13) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2618897342","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618897342?lang=en_us&edition=fundamental","pubTime":"2026-03-12 04:10","pubTimestamp":1773259807,"startTime":"0","endTime":"0","summary":"Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.13) by 9.09 percent. This is a 57.14 percent increase over losses of $(0.28) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51199102/tenaya-therapeutics-q4-eps-0-12-beats-0-13-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Tenaya Therapeutics Q4 EPS $(0.12) Beats $(0.13) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TNYA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618619973","title":"BRIEF-Tenaya Therapeutics Q4 Net Income USD -20.175 Million Vs. IBES Estimate USD -22 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2618619973","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618619973?lang=en_us&edition=fundamental","pubTime":"2026-03-12 04:05","pubTimestamp":1773259546,"startTime":"0","endTime":"0","summary":"Mar 11  - Tenaya Therapeutics Q4 operating expenses USD 20.775 million.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nPLXE5A63B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","TNYA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618973546","title":"Tenaya Therapeutics Q4 Operating Expenses USD 20.775 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2618973546","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618973546?lang=en_us&edition=fundamental","pubTime":"2026-03-12 04:05","pubTimestamp":1773259501,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nPLXE5A63B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","TNYA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618973969","title":"Press Release: Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2618973969","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618973969?lang=en_us&edition=fundamental","pubTime":"2026-03-12 04:05","pubTimestamp":1773259500,"startTime":"0","endTime":"0","summary":"Reported Promising Data for TN-201 and TN-401 Gene Therapies in Fourth Quarter of 2025; Additional Data Readouts and Pursuit of Regulatory Alignment for Each Program Planned in 2026. New Research Supports TN-301's Potential in Multiple Indications; Presented Preclinical Data for TN-301 in Duchenne Muscular Dystrophy Model. Entered into Multi-Target Research Collaboration with Alnylam Pharmaceuticals. December Financing with Net Proceeds of $55.8M and Anticipated Upfront Payment Extend Cash Runway into Second Half of 2027. Mr. Ali continued, \"We are also excited to take modest but important steps to move TN-301 -- our clinical-stage, highly selective, small molecule HDAC6 inhibitor -- forward towards patients. New preclinical data in relevant DMD models that we presented at the recent MDA meeting adds to a growing body of external evidence supporting the potentially broad clinical utility of TN-301 in a range of cardiac and cardiac-adjacent indications with high unmet patient need and l","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4099","BK4555","03160","BK4531","TNYA","BK4007","BK4139","BK4588","BK4604","TM","BK4539","HCM","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618627626","title":"Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301’s Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy","url":"https://stock-news.laohu8.com/highlight/detail?id=2618627626","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618627626?lang=en_us&edition=fundamental","pubTime":"2026-03-09 20:30","pubTimestamp":1773059400,"startTime":"0","endTime":"0","summary":"Tenaya’s Highly Selective HDAC6 Inhibitor TN-301 Outperformed Approved Pan-HDAC Inhibitor Givinostat in Improving Muscle Function and Correcting Drivers of DMD Cardiomyopathy New Data Confirm TN-301’s","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/09/3251810/0/en/Tenaya-Therapeutics-Presents-Preclinical-Data-at-MDA-2026-Highlighting-TN-301-s-Potential-to-Correct-Skeletal-and-Cardiac-Muscle-Decline-in-Duchenne-Muscular-Dystrophy.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","HCM","BK4539","BK4585","BK4007","TNYA","MDA","BK4531"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617542574","title":"Tenaya Therapeutics: Alnylam Partnership Validates Cardiovascular Platform and Supports Long-Term Buy Thesis","url":"https://stock-news.laohu8.com/highlight/detail?id=2617542574","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617542574?lang=en_us&edition=fundamental","pubTime":"2026-03-06 06:15","pubTimestamp":1772748923,"startTime":"0","endTime":"0","summary":"Tenaya Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Cory Jubinville, PhD from LifeSci Capital...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/tenaya-therapeutics-alnylam-partnership-validates-cardiovascular-platform-and-supports-long-term-buy-thesis-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/tenaya-therapeutics-alnylam-partnership-validates-cardiovascular-platform-and-supports-long-term-buy-thesis-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4585","BK4139","BK4581","XLV","CSII","XBI","LABU","BK4539","TNYA","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617527386","title":"Tenaya Therapeutics: Alnylam Collaboration De-Risks Platform and Expands Cardiovascular Upside, Supporting Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2617527386","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617527386?lang=en_us&edition=fundamental","pubTime":"2026-03-06 01:35","pubTimestamp":1772732120,"startTime":"0","endTime":"0","summary":"Joseph Pantginis, an analyst from H.C. Wainwright, maintained the Buy rating on Tenaya Therapeutics. The associated price target remains the same w...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/tenaya-therapeutics-alnylam-collaboration-de-risks-platform-and-expands-cardiovascular-upside-supporting-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/tenaya-therapeutics-alnylam-collaboration-de-risks-platform-and-expands-cardiovascular-upside-supporting-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TNYA","CSII"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617523546","title":"Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=2617523546","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617523546?lang=en_us&edition=fundamental","pubTime":"2026-03-05 22:08","pubTimestamp":1772719694,"startTime":"0","endTime":"0","summary":"Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatmentsMarch 5 (Reuters) - Tenaya Therapeutics TNYA.O said on Thursday it has signed a research deal with Alnylam Pharmace","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nL4N3ZT1BN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0882574055.USD","LU0109394709.USD","BK4585","LU0889565916.HKD","BK4139","ALNY","BK4548","BK4539","TNYA","LU0114720955.EUR","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617523580","title":"Tenaya Therapeutics Announces Major Cardiovascular Gene Target Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2617523580","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617523580?lang=en_us&edition=fundamental","pubTime":"2026-03-05 22:00","pubTimestamp":1772719229,"startTime":"0","endTime":"0","summary":"Tenaya Therapeutics ( ($TNYA) ) just unveiled an update. On March 4, 2026, Tenaya Therapeutics entered into a collaboration agreement with Alnylam ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tenaya-therapeutics-announces-major-cardiovascular-gene-target-collaboration?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tenaya-therapeutics-announces-major-cardiovascular-gene-target-collaboration?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CSII","BK4139","TNYA","BK4082","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617458540","title":"BRIEF-Tenaya Therapeutics Enters Into Research Collaboration With Alnylam Pharmaceuticals To Identify And Validate Novel Genetic Targets For Cardiovascular Disease Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2617458540","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617458540?lang=en_us&edition=fundamental","pubTime":"2026-03-05 21:31","pubTimestamp":1772717493,"startTime":"0","endTime":"0","summary":"BRIEF-Tenaya Therapeutics Enters Into Research Collaboration With Alnylam Pharmaceuticals To Identify And Validate Novel Genetic Targets For Cardiovascular Disease TherapeuticsMarch 5 (Reuters) - Alny","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nTUA7W8SVV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0882574055.USD","LU0109394709.USD","BK4585","LU0889565916.HKD","BK4139","ALNY","BK4548","BK4539","TNYA","LU0114720955.EUR","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617654013","title":"Tenaya Therapeutics Inc - Co to Validate up to 15 Gene Targets Under Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2617654013","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617654013?lang=en_us&edition=fundamental","pubTime":"2026-03-05 21:30","pubTimestamp":1772717400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nTUA7W8SVV:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0320765992.SGD","LU0882574055.USD","BK4585","LU0109394709.USD","ALNY","TNYA","BK4139","BK4539","LU0889565916.HKD","BK4548","BK4588","LU0114720955.EUR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tenayatherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0105},{"period":"1month","weight":-0.0019},{"period":"3month","weight":-0.1079},{"period":"6month","weight":-0.5201},{"period":"1year","weight":0.4549},{"period":"ytd","weight":-0.0287}],"compareEarnings":[{"period":"1week","weight":0.0144},{"period":"1month","weight":0.1051},{"period":"3month","weight":0.0386},{"period":"6month","weight":0.0537},{"period":"1year","weight":0.296},{"period":"ytd","weight":0.0539}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.091688},{"month":2,"riseRate":0.2,"avgChangeRate":-0.006231},{"month":3,"riseRate":0.4,"avgChangeRate":-0.077091},{"month":4,"riseRate":0.2,"avgChangeRate":0.069395},{"month":5,"riseRate":0.25,"avgChangeRate":-0.005732},{"month":6,"riseRate":0.25,"avgChangeRate":-0.069846},{"month":7,"riseRate":0.5,"avgChangeRate":-0.023292},{"month":8,"riseRate":0.4,"avgChangeRate":0.09529},{"month":9,"riseRate":0.4,"avgChangeRate":-0.101393},{"month":10,"riseRate":0.2,"avgChangeRate":-0.046678},{"month":11,"riseRate":0.4,"avgChangeRate":0.123533},{"month":12,"riseRate":0.2,"avgChangeRate":-0.128991}],"exchange":"NASDAQ","name":"Tenaya Therapeutics Inc","nameEN":"Tenaya Therapeutics Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tenaya Therapeutics Inc(TNYA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Tenaya Therapeutics Inc(TNYA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Tenaya Therapeutics Inc,TNYA,Tenaya Therapeutics Inc股票,Tenaya Therapeutics Inc股票老虎,Tenaya Therapeutics Inc股票老虎国际,Tenaya Therapeutics Inc行情,Tenaya Therapeutics Inc股票行情,Tenaya Therapeutics Inc股价,Tenaya Therapeutics Inc股市,Tenaya Therapeutics Inc股票价格,Tenaya Therapeutics Inc股票交易,Tenaya Therapeutics Inc股票购买,Tenaya Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tenaya Therapeutics Inc(TNYA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Tenaya Therapeutics Inc(TNYA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}